Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...
Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...
Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector ...
Osaka, Japan – Pancreatic cancer is an aggressive disease with few available treatments. Thankfully, researchers are hard at work to improve treatment options, and researchers from Japan have now ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results